A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2–11 years: a phase II preliminary report

Bernie Endyarni Medise1*, Soedjatmiko Soedjatmiko1, Hartono Gunardi1, Rini Sekartini1, Hindra Irawan Satari1, Sri Rezeki Hadinegoro1, Angga Wirahmadi1, Mita Puspita2, Rini Mulia Sari2, Jae Seung Yang3, Arijit Sil3, Sushant Sahastrabuddhe3 and Novilia Sjafri Bachtiar2

Abstract

Background: Typhoid fever caused by Salmonella enteric serovar Typhi (S. Typhi) is a common cause of morbidity in the world. In 2017, 14.3 million cases of Typhoid and paratyphoid fever occurred globally. School age children between 3 to 19 years old are the most affected. Poor sanitation and multi drug resistance have increased the need for vaccines to reduce the global burden of disease. Based on previous trials, typhoid conjugate vaccines have longer- lasting protection, higher efficacy, require fewer doses and are suitable from infancy that allows them to be incorporated into the routine immunization program. Our previous phase I trial proved that a novel Vi-DT typhoid conjugate vaccine is safe and immunogenic in subjects 2–5 and 18–40 years. Our phase II trial consisted of subjects 6 months to 40 years. Our previously published paper on subjects 6 to < 24 months proved that this vaccine is safe and immunogenic for this age group. Therefore, with this paper we aimed to evaluate the safety and immunogenicity in children 2–11 years.

Methods: A randomized, observer-blind, superiority design of Vi-DT Typhoid conjugate vaccine compared to Vi-polysaccharide vaccine (Vi-PS) phase II study was conducted from October 2018 to December 2018 where 200 subjects aged 2–11 years were recruited. A blood sample prior to vaccination was taken, followed by administration of a single dose of either test vaccine (Vi-DT) or control vaccine (Vi-PS) and then a second blood sample was collected 28 days post vaccination. Adverse reactions were assessed and antibody increment was evaluated at 28 days post vaccination through collected serum sample.

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Results: Pain was the most common local reaction. Fever and muscle pain were the most common systemic reactions. Both Vi-DT and Vi-PS groups had roughly the same number of adverse reactions. At 28 days post vaccination, 100% of subjects in the Vi-DT group and 93% of subjects in the Vi-PS group produced antibody increment ≥4 times. The Vi-DT group produced a higher GMT as compared to Vi-PS.

Conclusion: Vi-DT vaccine is safe and immunogenic in children 2–11 years old.

Trial registration: Trial registration number: NCT03460405.

Keywords: Immunogenicity, Safety, Typhoid conjugate vaccine, Vi-DT vaccine, Vi-PS vaccine

Background

Enteric fever caused by Salmonella enterica serovar Typhi (S. Typhi) and Salmonella enterica serovar Paratyphi (S. Paratyphi), is a common cause of morbidity in the world, especially in South and Southeast Asia [1–3]. In 2015, an estimated 17 million cases of typhoid and paratyphoid fever occurred globally, mostly in South and Southeast Asia and sub-Saharan Africa. Typhoid and paratyphoid fever may be fatal if left untreated with an estimate of 178,000 deaths worldwide in 2015 [4, 5].

The global burden of Disease Study estimated that in 2017, 14.3 million cases of typhoid and paratyphoid fever occurred globally, where 12.6% of the cases occurred in children below 5 years and 55.9% occurred in children younger than 15 years of age [6]. A recent study conducted in Asia and Africa aimed to compare the proportion of children with enteric fever in the age groups <5 years, 5–9 years and 10–14 years. The proportion of typhoid cases found in <5 years age group ranged from 14 to 29%, in those 5–9 years of age the range was 30 to 44% and in 10–14 years of age the range found was 28 to 52% [7, 8]. School-aged children above 5 years of age have been reported to have high rates of enteric fever with incidence rates up to four times higher than adult populations [8, 9].

The highest incidence of typhoid fever was found in impoverished, overcrowded regions with poor sanitation such as urban slum areas of North Jakarta (Indonesia), Kolkata (India) and Karachi (Pakistan) [1, 10]. The persistence of typhoid in many low- and middle-income countries in Asia and Africa is due to contamination of water supply by human waste [11, 12].

The symptoms of typhoid fever are highly variable which may be mild, characterized by low grade fever and malaise. It may however cause severe life-threatening systemic infection with multiple complications such as intestinal perforation, intestinal haemorrhage and encephalopathy [13]. Typhoid treatment consists of antibiotics; however, an increasing number of drug-resistant strains have been found in endemic countries that prolong treatment and make it costly [14].

Improvement in sanitation and provision of clean water contributed to a decline in typhoid fever cases in developing countries during the early twentieth century. However, this change was not significant in countries where typhoid fever remains endemic and antibiotic resistance is on the rise. Vaccinations play an important part in the measure to reduce the burden of disease [15, 16].

Current available typhoid vaccines, parenteral Vi-polysaccharide (Vi-PS) and live oral Ty21a are not licensed for infants and toddlers. Vi-PS vaccines are poorly immunogenic in children below 2 years whereas Ty21a is currently available only in enteric-coated capsules, which makes it impractical for infants and toddlers [14, 17, 18]. These existing vaccines can provide 50–70% protection for 3–5 years in individuals over 2 years of age, however considering the above shortcomings, the necessity for the development of Typhoid Conjugate Vaccines (TCVs) was felt. The 2017 WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommended the introduction of TCVs for infants and children aged >6 months in typhoid endemic countries [3, 19]. TCVs provide longer-lasting protection, higher efficacy, require fewer doses and are suitable from infancy that allows them to be incorporated into the routine immunization program [15, 20].

An example of TCV is Typhbar-TCV (Vi-polysaccharide conjugated to Tetanus toxoid), manufactured by Bharat Biotech International Limited, which through their 3-phase clinical trial, proved that it was safe, well tolerated and induced a robust and long-lasting response across age groups for long periods of time [17, 20, 21]. In addition to Typhbar-TCV, which is a WHO prequaliﬁed vaccine, there are 3 other TCVs licensed in India. A Vi- tetanus toxoid conjugate vaccine from PedaTyph which showed satisfactory results with significant immunogenicity post vaccination [14]. The first prototype TCV was developed by US NIH and they conjugated Vi to recombinant exotoxin A of Pseudomonas aeruginosa (Vi-rEPA vaccine) that has been proven to produce a strong immune response in infants and toddlers [7, 17]. A clinical trial in Philippines studied the safety and immunogenicity of a vaccine with Vi-polysaccharide conjugated to Diphtheria toxoid (Vi-DT). Their phase I trial was conducted on subjects 2–45 years of age and their phase II trial was conducted on subjects 6 to 23 months.
Both these phases of clinical trial proved that Vi-DT is safe, well-tolerated and immunogenic for the above age groups [22, 23].

This paper is a continuation of a previously published Phase I study involving subjects aged 2–5 years and 18–40 years as well as Phase II study involving subjects 6 to < 24 months [24, 25]. Although the phase II trial in subjects 2 to 11 years and 6 to < 24 months were held at the same time, the reports of these two age groups are being published separately due to some differences. First, there is no licensed Typhoid vaccine for children below 2 years in Indonesia, hence the control used in this age group was inactivated poliovirus vaccine whereas in children 2–11 years, the control used was an already licensed Vi-PS vaccine. Second, our phase I trial did not include children below 2 years therefore extra care had to be taken in this age group with 2 additional visit conducted, which was not the case in other age groups. Third, the objective of the trial in 6 to < 24 months group was safety and immunogenicity of Vi-DT vaccine whereas the objective of the trial on children 2–11 years was to compare safety and immunogenicity of Vi-DT to an already licensed vaccine. The results of the Phase I trial and phase II trial in children 6 to < 24 months proved that Vi-DT vaccine is safe with mild to moderate adverse effects and immunogenic with a significant increment in antibody GMT post vaccination. Hence, this study aims to evaluate the safety and immunogenicity of Vi-DT vaccine in children 2 to 11 years of age.

Methods

Study design

This study used a randomized, observer-blind, superiority design of Vi-DT vaccine compared to Vi-PS. A total of 200 children 2–11 years old were divided into 2 groups: half of them received Vi-DT and the other half Vi-PS.

Sample size

The maximum seroconversion rate among controls was assumed as 0.7. If the true seroconversion rate for Vi-DT vaccine subjects is 0.9, the study required 82 subjects each in Vi-DT and Vi-PS groups to be able to reject the null hypothesis that the seroconversion rates for experimental and control subjects are equal, with probability of 0.9. The Type I error probability associated with two sided test of this null hypothesis is 0.05. By assuming a 20% dropout and issues related to inadequate samples, we enrolled 100 subjects in each group.

Procedure

Inclusion criteria of this study were: healthy subjects age 2–11 years, parents or legal guardians agreed to abide by the rules of the study and visit schedule and signed the informed consent form.

Exclusion criteria were: subjects enrolled in another trial; had an axillary temperature of ≥37.5 °C; had a known history of allergy to any component of the vaccine; had a history of uncontrolled coagulopathy and receipt of treatment likely to alter immune response such as immunoglobulins, corticosteroids or other immunosuppressants. Subjects having an abnormality or chronic disease and subjects who previously suffered from typhoid fever (confirmed by blood culture or rapid test) were also excluded. Other exclusion criteria such as previous vaccination against typhoid fever; subjects already vaccinated with any vaccine within 1 month prior to vaccination or were expected to receive other vaccines within 1 month following vaccination and subjects who were planning to shift from the study area before the completion of the study.

After checking inclusion and exclusion criteria, the 200 subjects were recruited in such a way that 100 subjects received the experimental vaccine (Vi-DT) and 100 subjects received the control vaccine (Vi-PS). This allocation of groups was done by an unblinded team by giving the subject random codes which were unknown to the blinded investigators who were involved in recruitment, thereby, ensuring a non-biased result. The subjects were recruited by a team of blinded investigators from the Department of Child Health, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General National Hospital, Jakarta.

The trial consisted of 2 visits to a primary health center: Visit 1 and Visit 2. During Visit 1, a pre-vaccination blood sample was taken before which subjects were given a single dose of either Vi-DT or Vi-PS vaccine and immediate adverse events were evaluated after vaccination. Subjects were given diary cards where they had to note down their daily temperature and list all the local and systemic reactions that occurred up to the second visit as well as the severity and duration of each reaction. During visit 2 (28 days post vaccination), subjects were followed up on adverse events and a second blood sample was taken to evaluate increment in antibody titers. These visits were carried out in Senen (Central Jakarta) primary health center and Jatinegara (East Jakarta) primary health center.

Study intervention

The test vaccine used was Vi-DT vaccine produced by BioFarma which was injected intramuscularly in the left deltoid region. Each dose of this vaccine (0.5 mL) is composed of 25 μg of a purified Vi capsular polysaccharide of S. Typhi, 5 mg of 2-phenoxyethanol as preservative and 0.5 mL of phosphate buffer solution.

The control vaccine used was Vi-PS vaccine (Typhim Vi® produced by Sanofi), which is a licensed Typhoid
vaccine in Indonesia. It was also injected intramuscularly in the left deltoid region. Each dose of this vaccine (0.5 mL) is composed of 25 µg of purified Vi polysaccharide in a colorless isotonic phosphate buffer saline (pH 7±0.3), 4.150 mg of Sodium Chloride, 0.065 mg of Disodium Phosphate, 0.023 mg of Monosodium Phosphate, Phenol 0.25%, and 0.5 ml of sterile water for injection.

Safety evaluation
Immediate adverse effects (30 min post vaccination) were evaluated at visit 1. Delayed adverse effects (within 28 days post vaccination) were evaluated at visit 2. All local and systemic reactions, both immediate and delayed were recorded. This safety data was reviewed by a Data Safety Monitoring Board (DSMB). Vaccine safety data was analyzed using SPSS.

Immunogenicity evaluation
The blood obtained at each visit was shipped to a Clinical Trial Laboratory of BioFarma where antibody titers were blindly tested using ELISA. Anti-Vi IgG titers were determined based on the international standard serum, NIBSC 16/138 recommended by the WHO Expert Committee on Biological Standardization [26].

The antibody increment and GMT 28 days post immunization were evaluated. A four-fold increase of antibody titer compared to the baseline value, was considered as the measure of seroconversion. Immunogenicity data was analyzed using SPSS.

Pre vaccination titer levels for subjects with zero titer level were assigned a value of 0.000001 to enable GMT and titer increment calculations. Post vaccination titer levels increased significantly, hence no values were assigned for these.

Results
Two hundred subjects were recruited from October to December 2018 and followed up to 28 days post vaccination. There were no dropouts hence all 200 subjects were included in the data analysis. There were 104 females and 96 males. The mean age of subjects was 6.61 years for the Vi-DT group and 7.13 years for the Vi-PS group.

Safety
Overall, adverse reactions between Vi-DT and Vi-PS were similar except for a significant difference in delayed systemic reactions 72 h to 28 days post vaccination where these reactions were found higher in the Vi-PS group (Table 1). Up to 24 h post vaccination, pain was the most common local reaction followed by redness. Fever and muscle pain were the most common systemic reactions. Both Vi-DT and Vi-PS groups had roughly the same number of adverse reactions and hence there was no significant P value (Table 2). Most cases were of mild to moderate intensities except for some severe cases of

| Description | Vi-DT (%) | Vi-PS (%) | P value |
|-------------|-----------|-----------|---------|
| Immediate local reactions | 7 (n = 100) | 6 (n = 100) | 0.774 |
| Immediate systemic reactions | 2 (n = 100) | 1 (n = 100) | 1.00 |
| Delayed local reactions | 10 (n = 100) | 13 (n = 100) | 0.056 |
| Delayed systemic reactions | 8 (n = 100) | 8 (n = 100) | 1 |
| Delayed local reactions | 0 (n = 100) | 0 (n = 100) | 1 |
| Delayed systemic reactions | 1 (n = 100) | 2 (n = 100) | 1 |
| Delayed local reactions | 0 (n = 100) | 0 (n = 100) | 1 |
| Delayed systemic reactions | 2 (n = 100) | 2 (n = 100) | 1 |
| Delayed local reactions | 5 (n = 100) | 18 (n = 100) | 0.003* |

* Denotes a significant p value of < 0.05
|                   | Within 30 min | p  | 31 min to 72 h | p  | < 72 h to 28 days | p  |
|-------------------|---------------|----|----------------|----|------------------|----|
|                   | VI-DT         |    | VI-PS          |    | VI-DT            |    |
| Local Reaction    | Mild Moderate Severe |    | Mild Moderate Severe |    | Mild moderate Severe |    |
| Pain              | 6 0 0         | 0  | 6 0 0          | 0  | 7 0 0            | 0  |
|                   | 1 6 0         |    | 0 7 0          |    | 0 1 0            |    |
|                   | 0 0 0         |    | 0 0 0          |    | 0 0 0            |    |
|                   | 0 0 0         |    | 0 0 0          |    | 0 0 0            |    |
| Redness           | 0 0 0         | 0  | 1 0 0          | 0  | 1 2 0            | 0  |
|                   | 0 0 0         |    | 1 0 0          |    | 2 1 0            |    |
|                   | 0 0 0         |    | 0 1 0          |    | 0 0 0            |    |
|                   | 0 0 0         |    | 0 0 0          |    | 0 0 0            |    |
| Swelling          | 0 0 0         | 0  | 0 0 0          | 0  | − 0 0 0          | 0  |
|                   | 0 0 0         |    | 2 2 0          |    | 0 0 0            |    |
|                   | 0 0 0         |    | 0 0 0          |    | 0 0 0            |    |
| Induration        | 0 0 0         | 0  | 0 0 0          | 0  | − 0 0 0          | 0  |
|                   | 0 0 0         |    | 1 0 0          |    | 0 0 0            |    |
|                   | 0 0 0         |    | 1 0 0          |    | 0 0 0            |    |
| Other             | 0 0 0         | 0  | 0 0 0          | 0  | − 0 0 0          | 0  |
|                   | 0 0 0         |    | 0 0 0          |    | 0 0 0            |    |
| Systemic Event    |               |    |                |    |                  |    |
| Fever             | 0 0 0         | 0  | 0 0 0          | 0  | − 6 0 0          | 0  |
|                   | 0 0 0         |    | 2 1 3          |    | 1 9 2            |    |
|                   | 0 0 0         |    | 3 2 2          |    | 3 2 2            |    |
| Fatigue           | 1 0 0         | 0  | 1 0 0          | 0  | 1 1 0            | 0  |
|                   | 0 0 0         |    | 0 0 0          |    | 1 1 1            |    |
|                   | 0 0 0         |    | 0 0 0          |    | 0 0 0            |    |
| Muscle pain       | 0 0 0         | 1  | 0 0 0          | 0  | 1 2 1            | 0  |
|                   | 0 0 0         |    | 4 0 0          |    | 0 1 0            |    |
|                   | 0 0 0         |    | 0 0 0          |    | 0 0 0            |    |
| Other             | 0 0 0         | 0  | 0 0 0          | 0  | − 1 0 1          | 0  |
|                   | 0 0 0         |    | 0 0 0          |    | 0 0 0            |    |

Medise et al. BMC Pediatrics (2020) 20:480
Page 5 of 8
redness, swelling, induration and fever from 31 min to 72 h. Some severe cases of fever were also found from 72 h to 28 days post vaccination (Table 3). However, a majority of all cases, immediate and delayed, resolved within 48 h. There were no serious adverse events found up to 28 days post vaccination.

**Immunogenicity**

Anti-Vi IgG antibody titers were measured pre-vaccination and 28 days post vaccination. GMT at 28 days post vaccination drastically increased, with a significantly higher value in Vi-DT compared to Vi-PS ($p < 0.001$) (Table 4). At 28 days post vaccination, 100% of the subjects in the Vi-DT group experienced antibody increment ≥4-fold, whereas 93% of the subjects in the Vi-PS group experienced antibody increment ≥4-fold (Table 5).

**Discussion**

This phase II trial on subjects 2–11 years is a continuation of a previously published phase I trial [24]. In this age group, the Vi-DT conjugate vaccine resulted in minimal local and systemic adverse reactions. This vaccine also induced antibody responses in 100% of subjects with GMT titers significantly higher than Vi-PS vaccine. Thus, safety and immunogenicity of Vi-DT is now established for children 2–11 years.

The phase I trial was conducted on subjects 2–5 years and 18–40 years old [24]. This trial concluded that Vi-DT vaccine is safe, with minimal adverse effects and a single dose could produce a significant increment in anti-Vi IgG antibody levels. Based on these results, we decided to evaluate the safety and immunogenicity in children 2–11 years old. There were no dropouts, hence all 200 subjects participated in visit 1 and visit 2 and all were available for data analysis.

Previously, phase I randomized controlled trial of another Vi-DT vaccine (SK bioscience, South Korea) was conducted in the Philippines to evaluate safety and immunogenicity of a Vi-DT vaccine compared to Vi-PS vaccine in subjects 2–45 years old [22]. Pain at injection site was the most common immediate local reaction whereas fever was the most common immediate systemic reaction found in children. All cases were of mild to moderate severities except for one case of severe fever. There were no serious adverse events [22]. Our study is similar to this study in Philippines in regard to adverse reactions. We found that pain was the most common local reaction. Fever and muscle pain were the most common systemic reactions. There was no significant difference in reaction between Vi-DT and Vi-PS. Most cases were of mild to moderate intensities, except for some cases of severe fever found 72 h to 28 days post vaccination. These events were caused by bacterial or viral infections and resolved within 48 h without any complications. Similar to the Philippines study, our study did not have any serious adverse events up to 28 days post vaccination [24].

Previous phase 1 study of the Vi-DT vaccine (SK bioscience) conducted in Philippines showed that 100% of subjects in the Vi-DT group whereas 97% of subjects in the Vi-PS group showed seroconversion respectively. The Vi-DT group had a significantly higher GMT than the Vi-PS group ($p < 0.001$) [22]. Our trial also showed similar results where 100% of the subjects in the Vi-DT group showed antibody increment of ≥4 fold whereas 93% of subjects in the Vi-PS group showed increment of ≥4 fold as compared to baseline. GMT at 28 days post vaccination was also significantly higher in the Vi-DT group as compared to the Vi-PS group ($p < 0.001$) [24].

A randomized study in India aimed to evaluate safety and immunogenicity of a Vi- tetanus toxoid vaccine (PedaTyph™) in subjects 6 months to 12 years. They were given two doses of vaccines 6 weeks apart. Like our trial, this trial also had pain and fever as the most common adverse reactions. Identical to our trial, 100% of the subjects in this trial exhibited seroconversion at 6 weeks post vaccination [27].

Another randomized controlled study to evaluate the safety and immunogenicity of a Vi polysaccharide-tetanus toxoid vaccine (Typbar TCV) was carried out in India. This trial involved subjects 2 to 45 years. Similar to our trial, the most common adverse reaction found was fever. 97.3% of subjects who received TCV and 93.1% of subjects who received control (Vi-polysaccharide Typhbar) exhibited seroconversion. This value of seroconversion was found higher in our trial where 100% of the subjects who received Vi-DT TCV exhibited

| Group  | Increment of antibody titers V1 to V2 | $p$  | RR (95%CI)    |
|--------|--------------------------------------|------|---------------|
|        | $< 4$-fold                           | $≥ 4$-fold |           |
| Vi-DT  | 0                                   | 100%  | 0.014 (0.930 (0.881–0.981)|
| Vi-PS  | 7%                                  | 93%   |               |

**Table 4 Geometric mean titer (GMT) of antibody following vaccination**

| Vaccine         | GMT V1 (95%CI) Pre- vaccination | $p$  | GMT V2 (95%CI) 28 days post vaccination | $P$  |
|-----------------|---------------------------------|------|----------------------------------------|------|
| Vi-DT           | 0.0001445                       | 0.224 | 185.1685                               | <0.001|
| Vi-PS           | 0.0001281                       | 55.534402 |                                            |      |
seroconversion. Like our trial, this trial had significant GMT increment ($p < 0.001$) [17].

When compared to the phase II trial on children 6 to < 24 months, both these age groups had pain as the most common local reaction and fever as well muscle pain as the most common systemic reactions. Antibody increment for Vi-DT was slightly higher in 2–11 years age group compared to 6 to < 24 months group (100 and 98.99% respectively). GMT for both groups increased significantly [25].

Based on the safety and immunogenicity described in this study and previously published papers, it can be concluded that the typhoid conjugate Vi-DT vaccine is safe and immunogenic.

**Conclusion**

Our phase II study concluded that the novel typhoid conjugate Vi-DT vaccine is safe and immunogenic in children 2–11 years old.

**Abbreviations**

S. Typhi: Salmonella Typhi; Vi-DT: Vi polysaccharide conjugated to diphtheria toxoid; Vi-PS: Vi Polysaccharide; TCV: Typhoid conjugate vaccine; IgG: Immunoglobulin G; GMT: Geometric mean titer; WHO: World Health Organization; SAGE: Strategic Advisory Group of Experts on Immunization; Vi-REPA: Vi conjugated to Pseudomonas aeruginosa; ELISA: Enzyme-linked immunosorbent assay

**Acknowledgements**

The authors acknowledge the following colleagues for their contributions to this study: dr. Otty Mitha Sevianti, Spd, dr. Kania Adhyanisitha, Spd, Dr. dr. Aria Kekalih, dr. Sresha Mulki, Emi Triana Putri, SKM, Dita Rachmallia, Amd. Kom, Yuni Yudha Apriilla, Amrd. Keb. Romly Fadyla SE and Amelia Rahman, SE. Also, to the staff of Senen primary health center, dr. Indawati, M.Kes, dr. Anisa Hasnaini, dr. Edwinaitya Sekar Putri, Ifan Hanafi, Amrd. Kep AMK as well as the staff of Jatinegara primary health center, dr. Ma’mun, dr. Rosalia Linna Juniar, dr. Pudji Lestari Handayani, Muktiati, AMK, Wargiati, AMK, Meily Uli Artha Hariajan, Skep. Also, to Drs. Adrianiadjah Adhari, MM, from Bio Farma for their helpful support for the trial, Sue Kyongjo from WI for project management and Sooyeon Chang for administrative assistance.

**Authors’ contributions**

BEM designed and planned the study, composed the initial manuscript draft and reviewed and edited the final manuscript. SS, HG, RS, HIS, SRH and AW were involved in data collection and subject recruitment and critically reviewed the manuscript. NSB, RMS and MP designed the study, provided the vaccines, analyzed blood samples and critically reviewed the manuscript. JSY, AS and SSU reviewed the design of the study and critically reviewed the manuscript. All authors read and approved the final manuscript.

**Funding**

All steps of this study starting from study planning, recruitment, study continuity as well as salaries of investigators and research team were funded by PT Bio Farma, Indonesia.

**Availability of data and materials**

The datasets generated and analyzed during the current study are not publicly available because this a study on a new vaccine which is still ongoing and authors have a responsibility to the funding source to limit the data shared. However, these are available from the corresponding author on reasonable request.

This manuscript adheres to CONSORT guidelines.

**Ethics approval and consent to participate**

Trial registration was done and approved by ClinicalTrials.gov. Clinical trial registration number: NCT03460405. Registered 9th March 2018. URL: https://clinicaltrials.gov/ct2/show/NCT03460405

This trial was also registered and approved by the Ethics Committee of Universitas Indonesia with reference number 0276/UN2.F1/ETIK/2018 as well as Indonesian Trial Registry with registry number ITN-A-035T1PS. All parents of subjects were given an explanation of the trial as well as their rights and responsibilities as subjects, after which they signed an informed consent form.

**Consent for publication**

Not applicable.

**Competing interests**

This study was funded by PT Bio Farma, Indonesia. Data analysis and interpretation was solely done by investigators and the funding body was not involved in this process. The authors declare that they have no competing interests.

**Author details**

1. Department of Child Health, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo General National Hospital, Jalan Diponegoro no, Jakarta 71, Indonesia. 2. PT. Bio Farma, Bandung, Indonesia. 3. International Vaccine Institute, Seoul, Republic of Korea.

**Received:** 15 July 2020 Accepted: 7 October 2020

**Published online:** 15 October 2020

**References**

1. A. Azmatullah A, Qamar FN, Thaver D, Zaidi AK, Bhutta ZA. Systematic review of the global epidemiology, clinical and laboratory profile of enteric fever. J Glob Health. 2015;5:020407.

2. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. Clin Infect Dis. 2010;50:241–6. Medline: 2004951. https://doi.org/10.1086/649541.

3. Crump JA, Luby SP, Ed M. The global burden of typhoid fever. Bull World Health Organ. 2004;82:346–53 Medline:15298225.

4. Mogasale V, Maskery B, Ochial RL, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014;2:e570–80.

5. Radhalrishan A, Als D, Mintz ED, Cump JA, Stanaway J, Breiman RF, et al. Introductory article on global burden and epidemiology of typhoid fever. Am J Trop Med Hyg. 2018;99(Suppl 3):4–9. https://doi.org/10.4269/ajtmh.18-0032.

6. GBD. The global burden of typhoid and paratyphoid fever: a systematic analysis for the global burden of disease study 2017. Lancet Infect Dis. 2019;19:369–81. https://doi.org/10.1016/S1473-3099(18)30068-6.

7. Background paper on SAGE on Typhoid Vaccine Policy Recommendation. Prepared by the SAGE Working Group on Typhoid Vaccines and the WHO Secretariat. 24 September 2017.

8. Britto C, Pollard AJ, Voysey M, Böhmeke CJ. An appraisal of the clinical features of pediatric enteric fever: systematic review and meta-analysis of the age-stratified disease occurrence. Clin Infect Dis. 2017;64(11):1604–11. https://doi.org/10.1093/cid/cix229.

9. Feasey NA, Archer BN, Heydeman RS, et al. Typhoid fever and invasive nontyphoidal salmonellosis, Malawi and South Africa. Emerg Infect Dis. 2010;16:1448–51.

10. Ochial RL, Acosta CJ, Danovaro-Holiday MC, Balqing D, Bhattacharya SK, Agini MD, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2006;84:260–8. PMID: 16438514. https://doi.org/10.2471/BLT.06.039818.

11. Andrews JR, Qamar FN, Charles RC, Ryan ET. Extensively drug-resistant typhoid — are conjugate vaccines arriving just in time? N Engl J Med. 2018; 379:1493–5. https://doi.org/10.1056/NEJMep1803026.

12. Saha S, Islam M, Sajib M, Saha SH, Jamaluddin M, Hooda Y, et al. Burden and Paratyphoid and Paratyphoid: Implications for Vaccine Policy. Clin Infect Dis. 2019;68(Supplement_2),S117–23. https://doi.org/10.1093/cid/ciy1124.

13. Gibani MM, Britto C, Pollard AJ. Typhoid and paratyphoid fever: a call to action. Curr Opin Infect Dis. 2018;31:440–8. https://doi.org/10.1097/QCO. 0000000000000479.
14. Sahastrabuddhe S, Saluja T. Overview of the typhoid conjugate vaccine pipeline: current status and future plans. Infect Dis Soc Am. 2019. https://doi.org/10.1093/cid/ciy884.

15. Antillón M, Blicke J, Paltiel D, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 2017. https://doi.org/10.1016/j.vaccine.2017.05.001.

16. Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390:2472–80.

17. Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, Elia KM. Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study. Clin Infect Dis. 2015;61(3):393–402. https://doi.org/10.1093/cid/civ295.

18. Neuzil KM, Pollard AJ, Marfin AA. Introduction of typhoid conjugate vaccines in Africa and Asia. Infect Dis Soc Am. 2019. https://doi.org/10.1093/cid/ciy878.

19. World Health Organization. WHO Position Paper on Typhoid vaccines, vol. 93; 2018. p. 153–72.

20. Neuzil KM, Pollard AJ, Marfin AA. Introduction of typhoid conjugate vaccines in Africa and Asia. Infect Dis Soc Am. 2019. https://doi.org/10.1093/cid/ciy878.

21. Meiring JE, Patel P, Patel P, Gordon MA. Typhoid conjugate vaccines: making vaccine history in Africa. Expert Rev Vaccines. 2018;17:673–6. https://doi.org/10.1080/14760584.2018.1496825.

22. Capeding MR, Teshome S, Saluja T, Syed KA, Kim DR, Park JY, et al. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: phase I trial in healthy Filipino adults and children. Vaccine. 2018;36:3794–801.

23. Capeding MR, Alberto E, Sil A, Saluja T, Teshome S, Ryu Kim D, et al. Immunogenicity, safety and reactogenicity of a phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: a preliminary report. Vaccine. https://doi.org/10.1016/j.vaccine.2019.09.074.

24. Medise BE, Soedjatmiko S, Rennganis I, Gunardi H, Sekartini R, Koesno S, et al. Six-month follow up of a randomized clinical trial phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine. PLoS One. 2019;14(2):e0211784. https://doi.org/10.1371/journal.pone.0211784.

25. Medise BE, Soedjatmiko S, Gunardi H, Sekartini R, Satari HI, Hadinegoro SR, et al. One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: safety and immunogenicity of Vi-DT typhoid conjugate vaccine. Int J Infect Dis. 2020;93:102–7. https://doi.org/10.1016/j.ijid.2020.01.045.

26. Ripklemma S, Hockley J, Logana A, Bigdy P, Atkinson E, Jin C, et al. Establishment of the first international standard for human anti-typhoid capsular Vi polysaccharide IgG. Biologicals. 2018;56:29–38.

27. Mitra M, Shah N, Ghosh A, et al. Efficacy and safety of Vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: school-based cluster randomized study. Hum Vaccin Immunother. 2016;12:939–45.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.